United Therapeutics Corp
Change company Symbol lookup
Select an option...
UTHR United Therapeutics Corp
QNRX Quoin Pharmaceuticals Ltd
LNZA Lanzatech Global Inc
ADIL Adial Pharmaceuticals Inc
ANVS Annovis Bio Inc
LULU Lululemon Athletica Inc
VBLT Vascular Biogenics Ltd
MLEC Moolec Science SA
MLGO MicroAlgo Inc
AGRX Agile Therapeutics Inc

Health Care : Biotechnology | Mid Cap Value
Company profile

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso and Tyvaso DPI are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKinds Afrezza (insulin human) Inhalation Powder product.

Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

Today's volume of 38 shares is on pace to be much lighter than UTHR's 10-day average volume of 303,924 shares.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.

The EDGAR data presented on this website is sourced from the U.S. Securities and Exchange Commission (SEC), as available on https://www.sec.gov/edgar.shtml.